This program is supported by an independent education grant from Pfizer. This education program is only available to healthcare professionals in the USA.
Credits: AMA PRA Category 1 Credits™ (0.25.00 hours)
Type of activity: Enduring material (On-demand)
Launch date: September 16th 2026
Expiration date: December 31st 2027
Estimated time to complete this activity: 15 minutes
Prefer to read instead? Read our Key Clinical Summary here.
This is Module 3 of a three-part on-demand series: Module 1 and Module 2.
Activity Description
Join expert Dr. Shawn Dason, MD, for a practical, case-based exploration of how to proactively manage toxicities and sustain therapy in patients receiving PARP inhibitor combination regimens for metastatic prostate cancer. This session examines regimen-specific adverse event profiles—including severe anemia, neutropenia, and fatigue—and offers actionable strategies for dose modifications, complete blood count (CBC) monitoring, and managing drug-drug interactions. Through real-world clinical vignettes, participants will explore how to coordinate multidisciplinary care handovers across medical oncology, urology, pharmacy, and nursing to optimize adherence and maintain treatment continuity.
Session Highlights
- Apply evidence-based algorithms to manage hematologic toxicities, such as PARP inhibitor-induced anemia, using structured hold, transfusion, and dose-reduction protocols to sustain treatment.
- Implement regimen-specific CBC monitoring schedules and proactively evaluate treatable underlying causes of fatigue and cytopenias.
- Navigate critical administration requirements, drug-drug interactions, and medication adherence strategies, leveraging pharmacy collaboration to prevent therapeutic failure.
- Strengthen multidisciplinary care coordination and care-handover pathways across oncology, urology, pharmacy, and nursing teams to minimize care gaps during treatment.
Who Should Participate?
This program is designed for healthcare professionals directly involved in the diagnosis, targeted treatment, and longitudinal management of patients with metastatic prostate cancer (mPC), who seek to implement guideline-concordant genomic testing and multidisciplinary care into routine clinical practice.
- Oncology and Urology Practitioners (Academic and Community)
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
- Genetic Counselors
- Other Healthcare Professionals involved in the care and treatment of patients with mPC
Faculty
Dr Shawn Dason
Dr Shawn Dason is an Associate Professor of Urology and urologic oncologist at The Ohio State University, specializing in the surgical management of genitourinary cancers, including prostate cancer. His clinical expertise includes robotic and minimally invasive approaches to prostate cancer, with a focus on delivering individualized treatment tailored to each patient’s goals and needs. Dr Dason takes a multidisciplinary approach to care, working closely with colleagues across specialties to optimize outcomes. His research focuses on advancing innovative approaches to urologic cancer treatment and improving patient care.
Continuing Education Information
Commercial support: This activity received monetary support through an independent education grant from Pfizer.
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Disclosures
Dr Shawn Dason has no financial relationships within the past 24 months with any ineligible companies. Dr Dason does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.
These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.
Activity Accreditation for Health Professions
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses & Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.
Unapproved and/or off-label use disclosure
AffinityCE/MedAll requires CE faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
CME Inquiries
For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Participation Costs
There is no cost to participate in this program.
This continuing education activity is active starting September 16th 2026, and will expire on December 31st 2027..
Estimated time to complete this activity: 15 minutes.